Isolation, identification and expression of specific human CD133 antibodies

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Xia, Jing ^a   Zhang, Ying ^a   Qian, Jun ^a   Zhu, Xiaojun ^a   Zhang, Yafen ^a   Zhang, Jianqiong ^a   Zhao, Gang ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD133 ANTIGEN; GLYCOPROTEIN; HIS-HIS-HIS-HIS-HIS-HIS; HISTIDINE; HYBRID PROTEIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; OLIGOPEPTIDE; PEPTIDE; PROTEIN BINDING; SMALL INTERFERING RNA; TUMOR MARKER;

AMINO ACID SEQUENCE; CANCER STEM CELL; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANTIBODIES; ANTIGENS, CD; BASE SEQUENCE; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; HISTIDINE; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; NEOPLASTIC STEM CELLS; OLIGOPEPTIDES; PEPTIDES; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, DNA;

EID: 84888860467     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03320     Document Type: Article

References (28)

1. Clarke, M. F. et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66, 9339-9344 (2006). (Pubitemid 44623625)
2. Miraglia, S. et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90, 5013-5021 (1997). (Pubitemid 28007218)
3. Ma, S. & Guan, X. Y. MiRegulators in cancer stem cells of solid tumors. Cell Cycle 10, 571-572 (2011).
4. Kim, M. P. et al. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 6, e20636 (2011).
5. Hermann, P. C. et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323 (2007). (Pubitemid 47355323)
6. Marhaba, R., Klingbeil, P., Nuebel, T.,Nazarenko, I. Buechler, M. W. et al. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 8, 784-804 (2008).
7. Tsurumi, C. et al. Non-invasive in vivo imaging of tumor-associated CD133/prominin. PLoS One 5, e15605 (2010).
8. Vermeulen, L. et al. Single-cell cloning of colon cancer stem cells reveals a multilineage differentiation capacity. Proc Natl Acad Sci USA 105, 13427-13432 (2008).
9. Schneider, M., Huber, J., Hadaschik, B., Siegers, G. M., Fiebig, H. H. et al. Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker. BMC Cancer 12, 96 (2012).
10. Hagiwara, S. et al. Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br J Cancer 106, 1997-2003 (2012).
11. Ma, S. Biology and clinical implications of CD133(1) liver cancer stem cells. Exp Cell Res 319, 126-132 (2013).
12. Colombo, F. et al. Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma. PLoS One 6, e21369 (2011).
13. Hemmati, H. D. et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100, 15178-15183 (2003). (Pubitemid 37518036)
14. Jin, Z. H. et al. Basic studies on radioimmunotargeting of CD133-positive HCT116 cancer stem cells. Mol Imaging 11, 445-450 (2012).
15. Dubel, S., Stoevesandt, O., Taussig, M. J. & Hust, M. Generating recombinant antibodies to the complete human proteome. Trends Biotechnol 28, 333-339 (2010).
16. Thie, H., Meyer, T., Schirrmann, T., Hust, M. & Dubel, S. Phage display derived therapeutic antibodies. Curr Pharm Biotechnol 9, 439-446 (2008).
17. Thie, H. et al. Rise and fall of an anti-MUC1 specific antibody. PLoS One 6, e15921 (2011).
18. Perez-Martinez, D., Tanaka, T. & Rabbitts, T. H. Intracellular antibodies and cancer: new technologies offer therapeutic opportunities. Bioessays 32, 589-598 (2010).
19. Dobson, C. L. et al. Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism. MAbs 1, 552-562 (2009).
20. Yin, A. H. et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90, 5002-5012 (1997). (Pubitemid 28007217)
21. Gelderman, K. A., Tomlinson, S., Ross, G. D. & Gorter, A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25, 158-164 (2004). (Pubitemid 38249490)
22. Tomlinson, I. & Holliger, P. Methods for generating multivalent and bispecific antibody fragments. Methods Enzymol 326, 461-479 (2000).
23. Griffiths, A. D. & Duncan, A. R. Strategies for selection of antibodies by phage display. Curr Opin Biotechnol 9, 102-108 (1998). (Pubitemid 28098323)
24. Schaefer, J. V. & Pluckthun, A. Transfer of engineered biophysical properties between different antibody formats and expression systems. Protein Eng Des Sel 25, 485-506 (2012).
25. Zhu, X. et al. Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Mol Cancer Ther 9, 2131-2141 (2010).
26. Renaut, L. et al. Affinity maturation of antibodies: optimized methods to generate high-quality ScFv libraries and isolate IgG candidates by high-throughput screening. Methods Mol Biol 907, 451-461 (2012).
27. Weissleder, R., Kelly, K., Sun, E. Y., Shtatland, T. & Josephson, L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 23, 1418-1423 (2005). (Pubitemid 41679395)
28. Sambrook, J. & Russell, D. W. Preparation of Lysates Containing Fusion Proteins Encoded by Bacteriophage lambda Lysogens: Lysis of Bacterial Colonies. CSH Protoc 2006, (2006).